Highlights

• TruScreen Group Limited (NZX/ASX: TRU) confirmed its renounceable rights issue and shortfall bookbuild were substantially oversubscribed.
• Applications were received for 171,653,080 shares, 15% above the rights issue offer of 149,464,986 shares.
• The combined placement and rights issue raise totals just over NZ$4 million for the medical technology company.
• Shares are being allotted at the offer and bookbuild price of NZ$0.013 / A$0.011, with allotment on 30 June 2026.
• Directors intend to seek shareholder approval at a General Meeting expected on or around 28 July 2026 to allocate over-applied shares.

An ASX announcement from a small-cap medical technology company drew investor attention on 25 June 2026, as TruScreen Group Limited (NZX/ASX: TRU) revealed that its latest capital raising had been met with strong demand. The dual-listed health technology firm confirmed that its renounceable rights issue, together with an associated shortfall bookbuild, had been completed and were substantially oversubscribed. For Australian investors monitoring stock market news across the health technology sector, the update offered a snapshot of how shareholders responded to the company's funding effort.

The announcement is a follow-on from a 21 May 2026 disclosure of a NZ$2.9 million capital raise, and it provides fresh detail on the scale of investor participation in the rights issue. This market update outlines the key details of the company announcement, places it in sector context, and examines what the investor update may mean for those tracking the ASX stock under the ticker TRU. The article is informational in nature and does not provide any recommendation to buy, sell or hold ASX shares.

Company Overview

TruScreen Group Limited is a medical device company operating in the medical technology and health technology space. Its flagship product, the TruScreen Ultra device, is an AI-enabled, real-time cervical cancer screening device. According to the company, the device uses optical and electrical measurements to assess tissue, removing the need for tissue sampling or laboratory processing that is typical of conventional screening methods.

The company has built a broad regulatory and commercial footprint. The TruScreen Ultra device is CE Marked and EC certified, is ISO 13485 compliant, and is registered for clinical use with regulators including the Therapeutic Goods Administration (TGA) in Australia, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, the National Medical Products Administration (NMPA) in China, the Saudi Food and Drug Authority (SFDA) in Saudi Arabia, Roszdravnadzor in Russia and COFEPRIS in Mexico. The company has also secured Ministry of Health approval in Vietnam, Israel, Ukraine and the Philippines.

On a commercial level, TruScreen reports distributors in 29 countries and recognition within Chinese and other screening guidelines. In FY2024, the company states that more than 200,000 examinations were performed using its technology, with 200-plus devices installed across China, Vietnam, Mexico, Zimbabwe, Russia and Saudi Arabia. These metrics frame the operational base from which the company is now raising additional capital.

Announcement Summary

On 25 June 2026, TruScreen Group announced that its renounceable rights issue and shortfall bookbuild had been completed and were substantially oversubscribed. The company received applications for 171,653,080 shares, which represents 15% over the rights issue offer of 149,464,986 shares. The level of demand exceeding the offer size is the central element of this company announcement and the reason it has captured market attention.

Directors retained the offer price as the bookbuild price for shortfall applications and additional shares, meaning the same price applied across the entitlements and the shortfall component. The capital raising follows the company's 21 May 2026 announcement of a NZ$2.9 million capital raise, and the combined placement and rights issue raise now totals just over NZ$4 million.

Key Details from the Announcement

The company set out the allotment structure across three components. Investors reviewing the ASX company news may note the following details:

• Rights issue entitlements of 80,616,522 shares are to be allotted on 30 June 2026 at the offer price of NZ$0.013 / A$0.011.
• Shortfall shares of 68,848,464 are to be allotted on 30 June 2026 at the bookbuild price of NZ$0.013 / A$0.011, scaled based on shareholders' holdings at the record date of 28 May 2026.
• Directors intend to seek shareholder approval to allocate the over-applied shares of 22,188,094 at the bookbuild price, with a General Meeting expected on or around 28 July 2026.

Chairman Tony Ho said the company is delighted with strong shareholder support. He noted that the combined placement and rights issue raise totals just over NZ$4 million, and that the funds will allow the company to capitalise on significant opportunities in the year ahead. The company did not specify a detailed breakdown of how the proceeds will be allocated across specific projects or markets.

Why This Matters for ASX Investors

For Australian investors, an oversubscribed rights issue can be read as a signal of shareholder participation, though it is not a guarantee of future performance. The fact that applications came in at 15% above the offer size indicates that existing and participating shareholders were willing to commit further capital at the offer price. This investor update is therefore relevant to anyone holding or watching the ASX stock under the ticker TRU.

Capital raisings are a common mechanism for smaller medical technology and health technology companies that are still scaling commercialisation. The successful completion of the rights issue and shortfall bookbuild provides the company with funding it has stated will support opportunities in the year ahead. At the same time, any rights issue introduces dilution for shareholders who do not participate, and investors may watch how the additional shares affect the overall capital structure once allotted.

Because TruScreen is dual-listed on the NZX and ASX, Australian investors are also exposed to pricing expressed in both New Zealand and Australian dollars. Currency movements between the two markets are a factor that investors may consider when assessing the ASX shares.

Sector Context

The medical technology and health technology sectors continue to attract attention from investors seeking exposure to clinical innovation. Cervical cancer screening is an area of ongoing global health focus, and devices that aim to deliver real-time results without tissue sampling or laboratory processing sit within a broader trend toward point-of-care and AI-enabled diagnostics.

TruScreen's described regulatory clearances across multiple jurisdictions, its presence with distributors in 29 countries, and its installed base of more than 200 devices position it as a company with an established international footprint relative to many early-stage peers. The recognition of its technology in Chinese and other screening guidelines, together with the reported 200,000-plus examinations performed in FY2024, provides context on the clinical usage underpinning the company's commercial strategy.

Within this sector, capital raisings such as a rights issue are often used to fund commercialisation, distribution expansion and regulatory work.

Possible Market Reaction

Following a company announcement of this kind, market participants often look to trading activity for signs of how the news has been received. An oversubscribed rights issue may be interpreted by some investors as a vote of confidence from participating shareholders, while others may focus on the dilution that accompanies the issuance of new shares. The company did not specify any expectation regarding how its share price may respond.

In line with responsible reporting, this article makes no prediction about whether the ASX stock will rise or fall. Instead, investors may watch how the ASX ticker trades around the allotment date of 30 June 2026 and in the lead-up to the General Meeting expected on or around 28 July 2026. Market reaction to small-cap medical technology stocks can be volatile.

Risks and Uncertainties

As with any ASX announcement involving a capital raising, there are several risks and uncertainties that investors may wish to consider:

• Dilution: The issuance of new shares through the rights issue and shortfall bookbuild increases the total share count, which may dilute the holdings of shareholders who did not participate.
• Funding and commercialisation risk: While the company states the funds will allow it to capitalise on opportunities in the year ahead, there is no certainty that commercialisation efforts will achieve expected outcomes, and the company did not specify detailed financial targets.
• Regulatory risk: The company operates across multiple regulatory jurisdictions, and ongoing compliance with bodies such as the TGA, MHRA, NMPA and others is necessary; regulatory conditions can change.
• Shareholder-approval risk: The proposed allocation of the over-applied shares of 22,188,094 is subject to shareholder approval at a General Meeting expected on or around 28 July 2026, and that approval is not guaranteed.
• Market volatility: Small-cap medical technology shares can experience significant price volatility, independent of company-specific developments.
• Dual-listing and foreign exchange risk: As a company dual-listed on the NZX and ASX with pricing in both NZ and Australian dollars, movements in the exchange rate between the two currencies may affect the relative value of the ASX shares.

What to Watch Next

For those following this investor update, several upcoming milestones may warrant attention:

• The allotment of rights issue entitlements and shortfall shares on 30 June 2026 at the stated price of NZ$0.013 / A$0.011.
• The General Meeting expected on or around 28 July 2026, at which directors intend to seek shareholder approval to allocate the over-applied shares.
• Any further company announcement detailing how the just-over NZ$4 million in combined proceeds will be deployed across the year ahead.
• Updates on commercialisation progress, device installations and examination volumes across the company's international markets.
• Trading activity in the ASX ticker TRU around the key dates noted in this market update.

Conclusion

TruScreen Group's 25 June 2026 ASX announcement marks the completion of a substantially oversubscribed rights issue and shortfall bookbuild, with applications coming in 15% above the offer size. For a medical technology company operating in the cervical cancer screening space, the strong shareholder participation, as described by Chairman Tony Ho, contributes just over NZ$4 million in combined placement and rights issue funding that the company says will support opportunities in the year ahead.

For Australian investors and others tracking ASX company news, the key dates ahead include the 30 June 2026 allotment and the General Meeting expected on or around 28 July 2026, where the allocation of over-applied shares will be put to shareholders. As with any capital raising in the health technology sector, considerations such as dilution, commercialisation execution, regulatory compliance and market volatility remain relevant. Investors may watch how this ASX stock and its underlying business develop in the periods following the announcement.